Research programme: RNA interference-based therapeutics - Kylin Therapeutics

Drug Profile

Research programme: RNA interference-based therapeutics - Kylin Therapeutics

Alternative Names: pRNAi

Latest Information Update: 03 Feb 2011

Price : $50

At a glance

  • Originator Kylin Therapeutics
  • Class RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 12 Nov 2010 Preclinical development is ongoing in USA for cancer
  • 15 Jan 2009 pRNAi-based compounds are available for licensing for indications other than cancer (
  • 05 Jul 2007 Preclinical trials in Cancer in USA (Unspecified)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top